Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | USP14 | P54578 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19180264 | 0.78 | BACE1 (0.33) | BACE1 | |
| SCHEMBL19180882 | 0.76 | — | — | |
| SCHEMBL5373425 | 0.76 | MEN1 (0.49) | BACE1MEN1ALDH1A1KMT2A | |
| SCHEMBL17494744 | 0.75 | TDP1 (0.41) | BACE1USP14KDM4EMEN1ALDH1A1 | |
| SCHEMBL22678373 | 0.74 | MRGPRX4 (0.38) | BACE1USP14MEN1ALDH1A1KMT2A | |
| SCHEMBL8936718 | 0.73 | NOS3 (0.36) | BACE1USP14MEN1ALDH1A1KMT2A | |
| SCHEMBL22517612 | 0.73 | KDM5A (0.40) | BACE1USP14MEN1KMT2A | |
| SCHEMBL4996802 | 0.73 | IDO1 (0.38) | BACE1USP14MEN1ALDH1A1KMT2A | |
| SCHEMBL29383016 | 0.73 | NOS3 (0.36) | BACE1USP14MEN1ALDH1A1KMT2A | |
| SCHEMBL8936707 | 0.72 | CYP19A1 (0.40) | KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177287-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| US-10968193-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20170217918-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-08-03 | — | — | US | disclosed |
| EP-3177287-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016022742-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968193-B2 | Antidiabetic bicyclic compounds | GPR119, GPR65, GLP1R | BACE1 3392/4885USP14 4469/4885KDM4E 3801/4885 |
| US-20170217918-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | BACE1 3457/4885USP14 4449/4885KDM4E 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.